BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 2045206)

  • 1. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
    Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
    Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
    Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
    Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW; Beyers KL
    Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
    Teicher BA; Holden SA; al-Achi A; Herman TS
    Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
    Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
    Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
    Ning SC; Hahn GM
    Cancer Res; 1991 Nov; 51(21):5910-4. PubMed ID: 1718588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.